SCHEMBL19742639

SCHEMBL19742639

CCN(C(=O)O)N(C)c1ccc(N)cc1CS(C)(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.37
ACHE P22303 2/20 0.36
CYP19A1 P11511 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 2/20 0.32
CHRM2 P08172 1/20 0.32
CHRM3 P20309 1/20 0.32
MAOA P21397 1/20 0.32
HTR2C P28335 1/20 0.32
CHRNA4 P43681 1/20 0.32
HTR3A P46098 1/20 0.32
KCNH2 Q12809 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
MAPT P10636 1/20 0.31
CYP3A4 P08684 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19742682 0.83 GAA (0.33) PRKCIACHECYP19A1L3MBTL1GAA
SCHEMBL19742572 0.80 PRKCI (0.35) PRKCIACHECHRM2CHRM3MAOA
SCHEMBL19742636 0.72 CYP19A1 (0.34) PRKCIACHECYP19A1L3MBTL1CYP2C19
SCHEMBL19742646 0.72 PPIB (0.39) PRKCIACHECYP19A1L3MBTL1MAPT
SCHEMBL19742689 0.70 CYP19A1 (0.33) ACHECYP19A1L3MBTL1
SCHEMBL29355547 0.70 CYP19A1 (0.39) PRKCIACHECYP19A1L3MBTL1GAA
SCHEMBL19742811 0.69 CYP19A1 (0.32) ACHECYP19A1
SCHEMBL27564398 0.68 PRKCI (0.45) PRKCIACHECYP19A1GAACHRM2
SCHEMBL29355570 0.68 DAO (0.35) CYP19A1L3MBTL1HTR2C
SCHEMBL29151175 0.66 L3MBTL1 (0.42) PRKCIACHEL3MBTL1GAAKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3474855-B1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS INC (US) 2022-01-26 EP disclosed
EP-3474855-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF Polaris Pharmaceuticals, Inc. (US) 2019-05-01 EP disclosed
US-10227344-B2 CK2 inhibitors, compositions and methods thereof POLARIS PHARMACEUTICALS, INC. (US) 2019-03-12 US disclosed
WO-2017223432-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS (US) 2017-12-28 WO disclosed
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS 2017-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF CSNK1A1, CSNK2A1, CSNK2A3 PRKCI 67/4885ACHE 2707/4885CYP19A1 1135/4885
US-10227344-B2 CK2 inhibitors, compositions and methods thereof CSNK1A1, CSNK2A1, CSNK2A3 PRKCI 67/4885ACHE 2707/4885CYP19A1 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.